Long noncoding RNAs in cancer: From discovery to therapeutic targets

2020 ◽  
pp. 105-147 ◽  
Author(s):  
Ramesh Choudhari ◽  
Melina J. Sedano ◽  
Alana L. Harrison ◽  
Ramadevi Subramani ◽  
Ken Y. Lin ◽  
...  
Keyword(s):  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Long Noncoding Rnas

scholarly journals Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1424 ◽  
Author(s):  
Toshihiko Takeiwa ◽  
Kazuhiro Ikeda ◽  
Yuichi Mitobe ◽  
Kuniko Horie-Inoue ◽  
Satoshi Inoue
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Therapy Resistance ◽  
Long Noncoding Rnas ◽  
Endocrine Therapy Resistance ◽  
New Biomarkers

Long noncoding RNAs (lncRNAs) are defined as RNAs longer than 200 nucleotides that do not encode proteins. Recent studies have demonstrated that numerous lncRNAs are expressed in humans and play key roles in the development of various types of cancers. Intriguingly, some lncRNAs have been demonstrated to be involved in endocrine therapy resistance for breast cancer through their own mechanisms, suggesting that lncRNAs could be promising new biomarkers and therapeutic targets of breast cancer. Here, we summarize the functions and mechanisms of lncRNAs related to the endocrine therapy resistance of breast cancer.

scholarly journals Long Noncoding RNAs in Pathological Cardiac Remodeling: A Review of the Update Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Huan Zhou ◽  
Bin Wang ◽  
Ying-xi Yang ◽  
Qiu-jin Jia ◽  
Ao Zhang ◽  
...  
Keyword(s):  
Cardiac Remodeling ◽  
Vascular Remodeling ◽  
Target Gene ◽  
Myocardial Hypertrophy ◽  
Cardiac Fibroblasts ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Underlying Mechanism ◽  
Long Noncoding Rnas ◽  
Myocardial Remodeling

Cardiac remodeling is a self-regulatory response of the myocardium and vasculature under the stressful condition. Cardiomyocytes (CMs), vascular smooth muscle cells (VSMCs), endothelial cells (ECs), and cardiac fibroblasts (CFs) are all involved in this process, characterized by change of morphological structures and mechanical/chemical activities as well as metabolic patterns. Despite current development of consciousness, the control of cardiac remodeling remains unsatisfactory, and to further explore the underlying mechanism and seek the optimal therapeutic targets is still the urgent need in clinical practice. It is now emerging that long noncoding RNAs (lncRNAs) play key regulatory roles in these adverse responses: lncRNA TUG1, AK098656, TRPV1, GAS5, Giver, and Lnc-Ang362 have been indicated in hypertension-related vascular remodeling, H19, TUG1, UCA1, MEG3, APPAT, and lincRNA-p21 in atherosclerosis (AS), and HIF1A-AS1 and Lnc-HLTF-5 in aortic aneurysm (AA). In addition, Neat1, AK139328, APF, CAIF, AK088388, CARL, MALAT1, HOTAIR, XIST, and NRF are involved in postischemia myocardial remodeling, while Mhrt, Chast, CHRF, ROR, H19, Plscr4, and MIAT are involved in myocardial hypertrophy, and MALAT1, wisper, MEG3, and H19 are involved in extracellular matrix (ECM) reconstitution. Signaling to specific miRNAs by acting as endogenous sponge (ceRNA) was the main form that regulates the target gene expression during cardiac remodeling. This review will underline the updates of lncRNAs and lncRNA-miRNA interactions in maladaptive remodeling and also cast light on their potential roles as therapeutic targets, hoping to provide supportive background for following research.

Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer

2015 ◽  
Vol 19 (1) ◽  
pp. 14-20 ◽  
Author(s):  
V Mouraviev ◽  
B Lee ◽  
V Patel ◽  
D Albala ◽  
T E B Johansen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Long Noncoding Rnas ◽  
Novel Biomarkers
Sign in / Sign up

Export Citation Format

Share Document